Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity.
The melanocortin-3 and -4 receptors (MC3R, MC4R) have been implicated in energy homeostasis and obesity. Whereas the physiological role of the MC4R is extensively studied, little is known about the MC3R. One caveat is the limited availability of ligands that are selective for the MC3R. Previous studies identified Ac-His-DPhe(p-I)-Arg-Trp-NH 2, which possessed partial agonist/antagonist pharmacology at the mMC3R while retaining full nanomolar agonist pharmacology at the mMC4R. These data allowed for the hypothesis that the DPhe position in melanocortin tetrapeptides can be used to examine ligand side-chain determinants important for differentiation of mMC3R agonist versus antagonist activity. A series of 15 DPhe (7) modified Ac-His-DPhe (7)-Arg-Trp-NH 2 tetrapeptides has been synthesized and pharmacologically characterized. Most notable results include the identification of modifications that resulted in potent antagonists/partial agonists at the mMC3R and full, potent agonists at the mMC4R. These SAR studies provide experimental evidence that the molecular mechanism of antagonism at the mMC3R differentiates this subtype from the mMC4R.
Proneth
Bettina
B
Department of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, USA.
Pogozheva
Irina D
ID
Portillo
Federico P
FP
Mosberg
Henry I
HI
Haskell-Luevano
Carrie
C
D000818:Animals; D053486:Melanocortins / Q000737:chemistry* / Q000494:pharmacology; D051379:Mice; D044104:Receptor, Melanocortin, Type 3 / Q000819:agonists* / Q000037:antagonists & inhibitors; D055672:Static Electricity; D013329:Structure-Activity Relationship
D053486:Melanocortins; D044104:Receptor, Melanocortin, Type 3
J Med Chem. 2002 Jun 20;45(13):2801-10
12061882
Nature. 1994 Oct 27;371(6500):799-802
7935841
Nat Genet. 1998 Oct;20(2):113-4
9771699
Mol Endocrinol. 1994 Oct;8(10):1298-308
7854347
Endocrinology. 2000 Sep;141(9):3518-21
10965927
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
11517324
Cell. 1997 Jan 10;88(1):131-41
9019399
Science. 1992 Aug 28;257(5074):1248-51
1325670
Anal Biochem. 1995 Apr 10;226(2):349-54
7793637
Nat Genet. 1998 Oct;20(2):111-2
9771698
J Biol Chem. 1997 Sep 12;272(37):23000-10
9287296
Bioorg Med Chem Lett. 2003 Feb 24;13(4):649-52
12639550
J Med Chem. 2006 Feb 9;49(3):911-22
16451057
Biochemistry. 2005 Aug 30;44(34):11329-41
16114870
Hypertension. 2003 Nov;42(5):962-7
14568996
Biochemistry. 2005 Nov 8;44(44):14494-508
16262250
J Med Chem. 2006 Mar 23;49(6):1946-52
16539382
Br J Pharmacol Chemother. 1947 Sep;2(3):189-206
20258355
Anal Biochem. 1970 Apr;34(2):595-8
5443684
Biochemistry. 2000 Dec 5;39(48):14900-11
11101306
Biochemistry. 2006 Jan 31;45(4):1128-37
16430209
J Clin Invest. 2003 Apr;111(8):1251-8
12697744
J Biol Chem. 1993 Apr 15;268(11):8246-50
8463333
Trends Endocrinol Metab. 2000 Oct;11(8):304-8
10996524
J Med Chem. 1995 Sep 1;38(18):3454-61
7658432
Nat Genet. 1995 Nov;11(3):328-30
7581459
J Med Chem. 2002 Jul 4;45(14):3073-81
12086493
J Biol Chem. 1993 Jul 15;268(20):15174-9
8392067
J Med Chem. 2000 Dec 28;43(26):4998-5002
11150170
Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R560-7
16195498
Endocr Rev. 1980 Winter;1(1):1-27
6262069
J Pharmacol Exp Ther. 2003 Mar;304(3):1217-27
12604699
Bioorg Med Chem Lett. 2007 May 1;17(9):2492-8
17314042
J Biol Chem. 1976 Jul 10;251(13):4115-20
180015
Biochemistry. 2001 May 22;40(20):6164-79
11352754
Nat Genet. 2000 Sep;26(1):97-102
10973258
J Med Chem. 1989 Dec;32(12):2555-61
2555512
J Med Chem. 2002 Dec 19;45(26):5736-44
12477357
Gen Comp Endocrinol. 1989 Jan;73(1):157-63
2537778
Biotechniques. 1988 Jul-Aug;6(7):632-8
3273409
Cell. 1993 Mar 26;72(6):827-34
8458079
Peptides. 2003 Jan;24(1):73-82
12576087
Drug Des Discov. 1996 Dec;14(3):197-211
9017363
J Med Chem. 1987 Nov;30(11):2126-30
2822931
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8856-60
8415620